CanMED: NDC

Drug Name (Brand or Generic) Separate terms with OR to return results that match either term.

Major Class

Package in use from (mm/dd/yyyy):

To:

SEER*Rx Category

Clear All

10,000 Matching Results — Export these results

Click column titles once to sort ascending, and twice to sort descending.

Show Entries

NDC-11 (Package)	NDC-9 (Product)	Generic Name	Brand Name	Strength	SEER*Rx Category	Major Class (Descending)	Minor Class	Administration Route	Package Effective Date	Package Discontinuation Date	Status
00078-0401-34	00078-0401	Imatinib Mesylate	Gleevec	100.0 mg/1	Chemotherapy	Tyrosine Kinase Inhibitor	BCR-ABL	Oral	May 15, 2001		In Use
00093-7629-98	00093-7629	Imatinib Mesylate	Imatinib Mesylate	100.0 mg/1	Chemotherapy	Tyrosine Kinase Inhibitor	BCR-ABL	Oral	Aug. 4, 2016		In Use
00093-7630-56	00093-7630	Imatinib Mesylate	Imatinib Mesylate	400.0 mg/1	Chemotherapy	Tyrosine Kinase Inhibitor	BCR-ABL	Oral	Aug. 4, 2016		In Use
47335-0472-13	47335-0472	Imatinib Mesylate	Imatinib Mesylate	100.0 mg/1	Chemotherapy	Tyrosine Kinase Inhibitor	BCR-ABL	Oral	Feb. 1, 2016		In Use
47335-0472-81	47335-0472	Imatinib Mesylate	Imatinib Mesylate	100.0 mg/1	Chemotherapy	Tyrosine Kinase Inhibitor	BCR-ABL	Oral	Feb. 1, 2016		In Use
47335-0472-83	47335-0472	Imatinib Mesylate	Imatinib Mesylate	100.0 mg/1	Chemotherapy	Tyrosine Kinase Inhibitor	BCR-ABL	Oral	Feb. 1, 2016		In Use
47335-0472-88	47335-0472	Imatinib Mesylate	Imatinib Mesylate	100.0 mg/1	Chemotherapy	Tyrosine Kinase Inhibitor	BCR-ABL	Oral	Feb. 1, 2016		In Use
54868-5289-00	54868-5289	Imatinib Mesylate	Gleevec		Chemotherapy	Tyrosine Kinase Inhibitor	BCR-ABL	Oral	Oct. 7, 2005	June 30, 2013	No Longer Used
54868-5289-01	54868-5289	Imatinib Mesylate	Gleevec		Chemotherapy	Tyrosine Kinase Inhibitor	BCR-ABL	Oral	Oct. 7, 2005	June 30, 2013	No Longer Used
54868-5289-02	54868-5289	Imatinib Mesylate	Gleevec		Chemotherapy	Tyrosine Kinase Inhibitor	BCR-ABL	Oral	Oct. 7, 2005	June 30, 2013	No Longer Used
54868-5289-03	54868-5289	Imatinib Mesylate	Gleevec		Chemotherapy	Tyrosine Kinase Inhibitor	BCR-ABL	Oral	Oct. 7, 2005	June 30, 2013	No Longer Used
54868-5289-04	54868-5289	Imatinib Mesylate	Gleevec		Chemotherapy	Tyrosine Kinase Inhibitor	BCR-ABL	Oral	Oct. 7, 2005	June 30, 2013	No Longer Used
54868-5427-00	54868-5427	Imatinib Mesylate	Gleevec		Chemotherapy	Tyrosine Kinase Inhibitor	BCR-ABL	Oral	Nov. 9, 2005	June 30, 2013	No Longer Used
54868-5427-01	54868-5427	Imatinib Mesylate	Gleevec		Chemotherapy	Tyrosine Kinase Inhibitor	BCR-ABL	Oral	Nov. 9, 2005	June 30, 2013	No Longer Used
54868-5427-02	54868-5427	Imatinib Mesylate	Gleevec		Chemotherapy	Tyrosine Kinase Inhibitor	BCR-ABL	Oral	Nov. 9, 2005	June 30, 2013	No Longer Used
54868-5427-03	54868-5427	Imatinib Mesylate	Gleevec		Chemotherapy	Tyrosine Kinase Inhibitor	BCR-ABL	Oral	Nov. 9, 2005	June 30, 2013	No Longer Used
60429-0926-30	60429-0926	Imatinib Mesylate	Imatinib Mesylate	400.0 mg/1	Chemotherapy	Tyrosine Kinase Inhibitor	BCR-ABL	Oral	Dec. 30, 2016		In Use
60505-2900-00	60505-2900	Imatinib Mesylate	Imatinib Mesylate	100.0 mg/1	Chemotherapy	Tyrosine Kinase Inhibitor	BCR-ABL	Oral	Aug. 5, 2016		In Use
60505-2900-01	60505-2900	Imatinib Mesylate	Imatinib Mesylate	100.0 mg/1	Chemotherapy	Tyrosine Kinase Inhibitor	BCR-ABL	Oral	Aug. 5, 2016		In Use
60505-2900-03	60505-2900	Imatinib Mesylate	Imatinib Mesylate	100.0 mg/1	Chemotherapy	Tyrosine Kinase Inhibitor	BCR-ABL	Oral	Aug. 5, 2016		In Use
60505-2900-08	60505-2900	Imatinib Mesylate	Imatinib Mesylate	100.0 mg/1	Chemotherapy	Tyrosine Kinase Inhibitor	BCR-ABL	Oral	Aug. 5, 2016		In Use
60505-2900-09	60505-2900	Imatinib Mesylate	Imatinib Mesylate	100.0 mg/1	Chemotherapy	Tyrosine Kinase Inhibitor	BCR-ABL	Oral	Aug. 5, 2016		In Use
60505-2901-00	60505-2901	Imatinib Mesylate	Imatinib Mesylate	400.0 mg/1	Chemotherapy	Tyrosine Kinase Inhibitor	BCR-ABL	Oral	Aug. 5, 2016		In Use
60505-2901-01	60505-2901	Imatinib Mesylate	Imatinib Mesylate	400.0 mg/1	Chemotherapy	Tyrosine Kinase Inhibitor	BCR-ABL	Oral	Aug. 5, 2016		In Use
60505-2901-03	60505-2901	Imatinib Mesylate	Imatinib Mesylate	400.0 mg/1	Chemotherapy	Tyrosine Kinase Inhibitor	BCR-ABL	Oral	Aug. 5, 2016		In Use
60505-2901-05	60505-2901	Imatinib Mesylate	Imatinib Mesylate	400.0 mg/1	Chemotherapy	Tyrosine Kinase Inhibitor	BCR-ABL	Oral	Aug. 5, 2016		In Use
60505-2901-09	60505-2901	Imatinib Mesylate	Imatinib Mesylate	400.0 mg/1	Chemotherapy	Tyrosine Kinase Inhibitor	BCR-ABL	Oral	Aug. 5, 2016		In Use
60687-0192-21	60687-0192	Imatinib Mesylate	Imatinib Mesylate	100.0 mg/1	Chemotherapy	Tyrosine Kinase Inhibitor	BCR-ABL	Oral	Feb. 15, 2016		In Use
68382-0245-05	68382-0245	Imatinib mesylate	Imatinib mesylate	400.0 mg/1	Chemotherapy	Tyrosine Kinase Inhibitor	BCR-ABL	Oral	Jan. 21, 2021		In Use
68382-0245-06	68382-0245	Imatinib mesylate	Imatinib mesylate	400.0 mg/1	Chemotherapy	Tyrosine Kinase Inhibitor	BCR-ABL	Oral	Jan. 21, 2021		In Use
68382-0245-16	68382-0245	Imatinib mesylate	Imatinib mesylate	400.0 mg/1	Chemotherapy	Tyrosine Kinase Inhibitor	BCR-ABL	Oral	Jan. 21, 2021		In Use
68382-0245-78	68382-0245	Imatinib mesylate	Imatinib mesylate	400.0 mg/1	Chemotherapy	Tyrosine Kinase Inhibitor	BCR-ABL	Oral	Jan. 21, 2021		In Use
68382-0244-05	68382-0244	Imatinib mesylate	Imatinib mesylate	100.0 mg/1	Chemotherapy	Tyrosine Kinase Inhibitor	BCR-ABL	Oral	Jan. 21, 2021		In Use
68382-0244-16	68382-0244	Imatinib mesylate	Imatinib mesylate	100.0 mg/1	Chemotherapy	Tyrosine Kinase Inhibitor	BCR-ABL	Oral	Jan. 21, 2021		In Use
68001-0491-04	68001-0491	Imatinib mesylate	Imatinib mesylate	400.0 mg/1	Chemotherapy	Tyrosine Kinase Inhibitor	BCR-ABL	Oral	March 26, 2021		In Use
70771-1395-03	70771-1395	Imatinib mesylate	Imatinib mesylate	400.0 mg/1	Chemotherapy	Tyrosine Kinase Inhibitor	BCR-ABL	Oral	Jan. 21, 2021		In Use
70771-1395-05	70771-1395	Imatinib mesylate	Imatinib mesylate	400.0 mg/1	Chemotherapy	Tyrosine Kinase Inhibitor	BCR-ABL	Oral	Jan. 21, 2021		In Use
70771-1395-08	70771-1395	Imatinib mesylate	Imatinib mesylate	400.0 mg/1	Chemotherapy	Tyrosine Kinase Inhibitor	BCR-ABL	Oral	Jan. 21, 2021		In Use
70771-1395-09	70771-1395	Imatinib mesylate	Imatinib mesylate	400.0 mg/1	Chemotherapy	Tyrosine Kinase Inhibitor	BCR-ABL	Oral	Jan. 21, 2021		In Use
70771-1394-05	70771-1394	Imatinib mesylate	Imatinib mesylate	100.0 mg/1	Chemotherapy	Tyrosine Kinase Inhibitor	BCR-ABL	Oral	Jan. 21, 2021		In Use
70771-1394-09	70771-1394	Imatinib mesylate	Imatinib mesylate	100.0 mg/1	Chemotherapy	Tyrosine Kinase Inhibitor	BCR-ABL	Oral	Jan. 21, 2021		In Use
72606-0556-01	72606-0556	Imatinib mesylate	Imatinib mesylate	100.0 mg/1	Chemotherapy	Tyrosine Kinase Inhibitor	BCR-ABL	Oral	Nov. 6, 2019		In Use
72606-0557-01	72606-0557	Imatinib mesylate	Imatinib mesylate	400.0 mg/1	Chemotherapy	Tyrosine Kinase Inhibitor	BCR-ABL	Oral	Nov. 6, 2019		In Use
62332-0565-30	62332-0565	ERLOTINIB HYDROCHLORIDE	ERLOTINIB HYDROCHLORIDE	25.0 mg/1	Chemotherapy	Tyrosine Kinase Inhibitor	EGFR	Oral	July 9, 2021		In Use
62332-0565-90	62332-0565	ERLOTINIB HYDROCHLORIDE	ERLOTINIB HYDROCHLORIDE	25.0 mg/1	Chemotherapy	Tyrosine Kinase Inhibitor	EGFR	Oral	July 9, 2021		In Use
62332-0566-30	62332-0566	ERLOTINIB HYDROCHLORIDE	ERLOTINIB HYDROCHLORIDE	100.0 mg/1	Chemotherapy	Tyrosine Kinase Inhibitor	EGFR	Oral	July 9, 2021		In Use
62332-0566-90	62332-0566	ERLOTINIB HYDROCHLORIDE	ERLOTINIB HYDROCHLORIDE	100.0 mg/1	Chemotherapy	Tyrosine Kinase Inhibitor	EGFR	Oral	July 9, 2021		In Use
62332-0567-30	62332-0567	ERLOTINIB HYDROCHLORIDE	ERLOTINIB HYDROCHLORIDE	150.0 mg/1	Chemotherapy	Tyrosine Kinase Inhibitor	EGFR	Oral	July 9, 2021		In Use
62332-0567-90	62332-0567	ERLOTINIB HYDROCHLORIDE	ERLOTINIB HYDROCHLORIDE	150.0 mg/1	Chemotherapy	Tyrosine Kinase Inhibitor	EGFR	Oral	July 9, 2021		In Use
50419-0488-58	50419-0488	Sorafenib	Nexavar	200.0 mg/1	Chemotherapy	Tyrosine Kinase Inhibitor	VEGFR, FGF, PDGFR, KIT, RET, CRAF, BRAF	Oral	Dec. 20, 2005		In Use

1 …
4
5
6
7
8
9
10
… 200

Found 10,000 results in 4 milliseconds — Export these results

CanMED and the Oncology Toolbox

CanMED: NDC